Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer
Por:
Ganz P, Bandos H, Spanic T, Friedman S, Mueller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas E, Armstrong A, Im S, Song C, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Lee K, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek S, Bane C, Mccarron E, Mita M, Rossi G, Rastogi P, Fielding A, Gelber R, Scheepers E, Cameron D, Garber J, Geyer C, Tutt A
Publicada:
10 abr 2024
Resumen:
|